Adenocarcinoma
FDA approves NDA to market Mitozytrex
Published in Cancer Weekly, December 24th, 2002
SuperGen, Inc., (SUPG) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Mitozytrex (MitoExtra), the company's proprietary version of the generic drug mitomycin, for use in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed.
Mitozytrex becomes the first approved drug based on SuperGen's patented 'supergenerics' Extra technology platform.
"We are very pleased to have received FDA clearance to market Mitozytrex. This approval marks a milestone as it is the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2002-12-24)
More Articles from Cancer Weekly
- Cancer Research
Chromogranin A could be marker for primary liver cancers - Pancreatic Cancer Metastasis
Vector allows 5-fluorouracil to fight disseminated pancreatic cancer - Ewing Sarcoma
Imatinib shows early promise - Gliomas
Suicide gene therapy sustains antitumor activity in murine model - Liver Cancer Therapy
Embolization feasible for treating certain hepatocellular carcinoma patients - Multiple Myeloma
Combination of oral therapies could supplant infused agents - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
